netFormulary NHS
Ipswich and East Suffolk CCG
North East Essex CCG
East Suffolk and North East Essex NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Hospital only guidance

 Details...
08.02.03  Expand sub section  Anti-lymphocyte monoclonal antibodies
Alemtuzumab (injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red Hospital

MHRA: Serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements


 
Link  NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
   
Cytotoxic Drug IsatuximabBlack Triangle (injection)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Formulary
Red Hospital
High Cost Medicine
NHS England
 
Link  NICE TA658 Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
   
Obinutuzumab (injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red Hospital
High Cost Medicine
 
Link  NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma
Link  NICE TA343: Obinutuzumab with chlorambucil for CLL
Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Link  NICE TA629 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Link  NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
   
Ofatumumab (injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red Hospital
High Cost Medicine
 
Link  NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
   
Rituximab
View adult BNF View SPC online View childrens BNF
Formulary
Red Hospital
High Cost Medicine

Hospital only guidance

Must be prescribed by brand name

See IHT newsletter below for further information

Existing patients

Continue using MabThera® unless a switch has been agreed (NB-subcutaneous MabThera will remain the same in NHL)

New patients

New patients requiring IV rituximab will be prescribed Truxima®.

See IHT newsletter below for further information

 
Link  IHT- Introduction of Biosimilar Rituximab (Truxima®)
Link  NICE TA561 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Link  NICE TA609 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Blue

For routine prescribing in primary and secondary care.   

Green

Initiated (if clinically urgent) or advised (if non-urgent) by specialist in secondary care, prescribing can be continued in primary care.   

Amber

Shared care  

Red Hospital

Hospital only  

Double Red

There should be no prescribing of these drugs  

Mixed

The traffic light of the drug is dependant on the indication. Please see individual drug entry for details  

netFormulary